{"result": "(\"entity\"<|>UPROPION<|>EVENT<|>Upropion is a medication studied for its effects on weight loss in overweight and obese adults through a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.)\n##\n(\"entity\"<|>COR-I<|>EVENT<|>COR-I is a phase 3 clinical trial that investigates the effects of upropion on weight loss in overweight and obese adults.)\n##\n(\"entity\"<|>NALTREXONE SR/BUPROPION SR<|>EVENT<|>Naltrexone SR/bupropion SR is a combination therapy studied for its effects on weight and obesity-related risk factors in overweight and obese patients.)\n##\n(\"entity\"<|>COR-II<|>EVENT<|>COR-II is a randomized, phase 3 trial that evaluates the effects of naltrexone SR/bupropion SR on weight and obesity-related risk factors.)\n##\n(\"entity\"<|>COR-DIABETES<|>EVENT<|>COR-Diabetes is a study that examines the effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.)\n##\n(\"entity\"<|>COR-BMOD<|>EVENT<|>COR-BMOD is a trial that assesses weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification.)\n##\n(\"entity\"<|>NALTREXONE-BUPROPION<|>EVENT<|>Naltrexone-bupropion is a medication studied for its effect on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors.)\n##\n(\"entity\"<|>GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS<|>EVENT<|>Glucagon-like peptide-1 receptor agonists are medications studied for their effects on weight loss in type 2 diabetes.)\n##\n(\"entity\"<|>LIRAGLUTIDE<|>EVENT<|>Liraglutide is a human glucagon-like peptide-1 analog studied for its efficacy and safety in combination with metformin and thiazolidinedione in patients with type 2 diabetes.)\n##\n(\"entity\"<|>LEAD-4 MET+TZD<|>EVENT<|>LEAD-4 Met+TZD is a study evaluating the efficacy and safety of liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes.)\n##\n(\"entity\"<|>SCALE DIABETES<|>EVENT<|>SCALE Diabetes is a randomized clinical trial assessing the efficacy of liraglutide for weight loss among patients with type 2 diabetes.)\n##\n(\"entity\"<|>SCALE MAINTENANCE<|>EVENT<|>SCALE Maintenance is a randomized study that investigates weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss.)\n##\n(\"entity\"<|>SCALE SLEEP APNEA<|>EVENT<|>SCALE Sleep Apnea is a randomized clinical trial studying the effect of liraglutide in individuals with obesity and moderate or severe obstructive sleep apnea.)\n##\n(\"entity\"<|>LEADER TRIAL<|>EVENT<|>LEADER Trial is a study that examines liraglutide and cardiovascular outcomes in type 2 diabetes.)\n##\n(\"entity\"<|>CETILISTAT<|>EVENT<|>Cetilistat is a medication studied for weight loss, HbA1c reduction, and tolerability in a randomized, placebo-controlled trial.)\n##\n(\"relationship\"<|>UPROPION<|>COR-I<|>Upropion is the subject of the COR-I trial which investigates its effects on weight loss in overweight and obese adults<|>8)\n##\n(\"relationship\"<|>NALTREXONE SR/BUPROPION SR<|>COR-II<|>Naltrexone SR/bupropion SR is the focus of the COR-II trial which evaluates its effects on weight and obesity-related risk factors<|>8)\n##\n(\"relationship\"<|>NALTREXONE SR/BUPROPION SR<|>COR-DIABETES<|>Naltrexone SR/bupropion SR is studied in the COR-Diabetes trial for its effects on body weight and glycemic parameters<|>8)\n##\n(\"relationship\"<|>NALTREXONE SR/BUPROPION SR<|>COR-BMOD<|>Naltrexone SR/bupropion SR is the treatment evaluated in the COR-BMOD trial for weight loss as an adjunct to behavior modification<|>8)\n##\n(\"relationship\"<|>NALTREXONE-BUPROPION<|>NALTREXONE SR/BUPROPION SR<|>Naltrexone-bupropion is a combination therapy that includes naltrexone SR/bupropion SR<|>7)\n##\n(\"relationship\"<|>GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS<|>LIRAGLUTIDE<|>Liraglutide is a type of glucagon-like peptide-1 receptor agonist studied for weight loss<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDE<|>LEAD-4 MET+TZD<|>Liraglutide is evaluated in the LEAD-4 Met+TZD study for its efficacy and safety in type 2 diabetes<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDE<|>SCALE DIABETES<|>Liraglutide is the focus of the SCALE Diabetes trial assessing its efficacy for weight loss in type 2 diabetes<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDE<|>SCALE MAINTENANCE<|>Liraglutide is studied in the SCALE Maintenance trial for weight maintenance after low-calorie-diet-induced weight loss<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDE<|>SCALE SLEEP APNEA<|>Liraglutide is evaluated in the SCALE Sleep Apnea trial for its effects on individuals with obesity and sleep apnea<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDE<|>LEADER TRIAL<|>Liraglutide is the subject of the LEADER Trial which examines its cardiovascular outcomes in type 2 diabetes<|>8)\n##\n(\"relationship\"<|>CETILISTAT<|>NALTREXONE-BUPROPION<|>Cetilistat is studied in a similar context as naltrexone-bupropion for weight loss<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: upropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010; 376: 595-605.\n\n18. Apovian CM, Aronne L, Rubino D,Still C, Wyatt H, Burns C, et al;COR-II Study Group. A randomized, phase 3 trial ofnaltrexone SR/bupropion SR on weight andobesity-related risk factors (COR-II). Obesity (SilverSpring). 2013; 21:935-943.\n\n19. Hollander P, Gupta AK, Plodkowski R,Greenway F, Bays H, Burns C, et al;COR-Diabetes Study Group. Effects of naltrexonesustained-release/bupropion sustained-releasecombination therapy on body weight and glycemicparameters in overweight and obese patients withtype 2 diabetes. Diabetes Care. 2013; 36:4022-4029.\n\n20. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011; 19:110-120.\n\n21. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016; 315:990-1004.\n\n22. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368: 1696-1705.\n\n23. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009; 32:1224-30.\n\n24. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012; 344:d7771.\n\n25. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean MEJ, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36: 843-54.\n\n26. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M. et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New Engl J Med. 2015; 373:11-22.\n\n27. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Vang Skjøth T, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes. The SCALE Diabetes randomized clinical trial. JAMA. 2015; 14:687-99.\n\n28. Wadden TA, Hollander P, Klein S, Niswender S, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes. 2013; 37: 1443-51.\n\n29. Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T. et al. Effect of liraglutide 3.0mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep. Apnea randomized clinical trial. Int J Obes. 2016; 40:1310-9.\n\n30. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 28; 375: 311-22.\n\n31. Fujioka K, O'Neil PM, Davies M, Greenway F, C W Lau D, Claudius B, et al. Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring). 2016; 24:2278-2288.\n\n32. Kopelman P, Groot GH, Rissanen A, Rossner S, Toubro S, Palmer R, Hallam R, Bryson A, Hickling RI. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled\n---\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}